Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Spain / NCT05624632
Enrolling by invitation Observational

Cognitive Remote Assessment Using FLAME (CRA-FLAME)

NCT05624632 · tracked via the Priya Life Science Spain tracker
Sponsor
Barcelonabeta Brain Research Center, Pasqual Maragall Foundation
Phase
Observational
Started
2022-12-01
Last updated
2025-05-31

Condition(s) studied

Cognitive Impairment

Investigational drug(s) / intervention(s)

Remote cognitive testing

Remote cognitive testing: Remote cognitive testing

Study summary

We aim to use a multimodal approach comprising conventional neuropsychological cognitive tests, fluid and imaging biomarker data, to explore their association with the FLAME unsupervised cognitive computerized assessment. We believe that this would provide critical information to move forward the current research framework in the field.

Participants will be selected from BBRC-sponsored studies, such as the ALFA project (STUDY 45-65 FPM/2012), the ALFA+ cohort study (ALFA - FPM - 0311), the Beta-AARC study (β-AARC\_BBRC2020) or the BarcelonaBeta Dementia Prevention Research Clinic study (BBRC-DemPrev-2018)

Eligibility

Sex
ALL
Min age
45 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: Participants must meet ALL the following criteria: 1. To sign the study informed consent form approved by the corresponding authorities. 2. Men and women that have participated/are participating in a BBRC-sponsored study. 3. To accept that: * The results obtained in this study may be published in scientific journals and at BBRC's communication channels (e.g. web page) * The data gathered may be used in combination with those gathered in other BBRC-sponsored studies in which they may (have) participate(d) Exclusion Criteria: 1\. Not having an ICT literacy enough to access and complete the online tests.

Primary outcome measure(s)

  • FLAME global composite score — through study completion, an average of 3 years
    calculated by combining information from two web-based online neuropsychological test batteries that are already integrated in a unique platform: the PROTECT Cognitive Tests System (PCTS) (Corbett et al., 2015) and the CogTrackTM (Wesnes et al., 2017)

Trial sites (1)

FacilityCityRegionStatus
BarcelonaBeta Brain Research Center Barcelona Spain

More Barcelonabeta Brain Research Center, Pasqual Maragall Foundation trials in Spain

Personalized Brain Health Service and Dementia Prevention Recruiting
β-AARC: Cohort Study for the Identification of Blood-based Biomarkers in a Population With Subjective Cognitive Decline Active, not recruiting
Brain Characterization of Amyloid Protein and Glucose Metabolism of ALFA Project Participants Recruiting
Early Identification of Markers in Alzheimer's Families / ALFA Active, not recruiting
PENSA+: Extended Follow-up of a Multimodal Lifestyle Intervention to Prevent Cognitive Decline in APOE-ε4 Carriers Starting soon

Other trials for the same condition

Motor-cognitive Training Effects on Cognition in Breast Cancer Survivors: the BRAINonFIT Study (BRAINonFIT). Active, not recruiting
Non-Invasive Brain Stimulation and Cognitive Training for Depressive Symptomatology Related to Breast Cancer (ONCODEP) Active, not recruiting
Early Cognitive Interventions in Digital Format for Cancer Survivors Recruiting
Early Neuropsychological Rehabilitation and Family Psychoeducation After Ischemic Stroke Active, not recruiting
A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05624632 on ClinicalTrials.gov ↗ ← All trials in Spain